Figg William Douglas, Newell David R
Authors' Affiliations: Clinical Pharmacology Program, Office of the Clinical Director, Molecular Pharmacology Section and Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; and Northern Institute for Cancer Research, Newcastle University, Newcastle, United Kingdom
Clin Cancer Res. 2014 May 15;20(10):2525-9. doi: 10.1158/1078-0432.CCR-14-0511.
Clinical pharmacologic research plays a vital role in cancer drug development. In recent years, biomarker studies have become integral to this process, specifically the use of pharmacologic biomarkers in the development of targeted therapies and their translation to clinical practice. In this overview, we discuss the validation of pharmacodynamics (PD) biomarkers and highlight the circulating tumor DNA as a promising cancer biomarker to illustrate how PD biomarkers can be powerful tools for guiding treatment strategies. We provide insights into PD biomarker approaches for future development of novel therapies and their role in cancer medicine. See all articles in this CCR focus section, "Progress in pharmacodynamic endpoints."
临床药理学研究在癌症药物研发中起着至关重要的作用。近年来，生物标志物研究已成为这一过程不可或缺的一部分，特别是在靶向治疗药物研发及其转化为临床实践过程中使用的药理学标志物。在本综述中，我们讨论了药效学（PD）标志物的验证，并强调循环肿瘤DNA作为一种有前景的癌症标志物，以说明PD标志物如何能够成为指导治疗策略的有力工具。我们深入探讨了PD标志物方法在新型疗法未来研发中的应用及其在癌症医学中的作用。请参阅本期《临床癌症研究》聚焦部分的所有文章，“药效学终点的进展”。
